Biobank Program for Personalized Medicine Hits 25K Enrollees
Twenty-five thousand individuals now have enrolled in the Mount Sinai Biobank Program of Mount Sinai Medical Center in New York, the organization announced on April 29.
Twenty-five thousand individuals now have enrolled in the Mount Sinai Biobank Program of Mount Sinai Medical Center in New York, the organization announced on April 29.
The program launched in 2007 with a donation from The Andrea and Charles Bronfman Philanthropies. Called BioMe, participants consent to DNA sequencing, contact from researchers and longitudinal studies from data in the hospital’s electronic health records. BioMe is a repository of DNA and plasma samples linked to clinical data in the EHR.
Research in 2011 found that use of ethnic labels may no longer be helpful in predicting disease risk or how a patient will respond to certain medications, according to Mount Sinai. Findings showed that nearly 1,000 BioMe participants self-identified as European-American, African-American or Hispanic had considerable parts of their genomic makeup coming from mixed African or European ancestry.
More recently, work has finished at the hospital on development of new software to merge the genomic and clinical data and give physicians real-time therapeutic guidance based on a patient’s genetic profile. The software is called “CLIPMERGE” for Clinical Implementation of Personalized Medicine through Electronic Health Records and Genomics. It now is being gradually implemented and among other benefits, will aid physicians in prescribing more effective medications. CILPMERGE presently is being used for guidance in treating cardiovascular disease, blood clots and high cholesterol.
Information on BioMe is available here.
The program launched in 2007 with a donation from The Andrea and Charles Bronfman Philanthropies. Called BioMe, participants consent to DNA sequencing, contact from researchers and longitudinal studies from data in the hospital’s electronic health records. BioMe is a repository of DNA and plasma samples linked to clinical data in the EHR.
Research in 2011 found that use of ethnic labels may no longer be helpful in predicting disease risk or how a patient will respond to certain medications, according to Mount Sinai. Findings showed that nearly 1,000 BioMe participants self-identified as European-American, African-American or Hispanic had considerable parts of their genomic makeup coming from mixed African or European ancestry.
More recently, work has finished at the hospital on development of new software to merge the genomic and clinical data and give physicians real-time therapeutic guidance based on a patient’s genetic profile. The software is called “CLIPMERGE” for Clinical Implementation of Personalized Medicine through Electronic Health Records and Genomics. It now is being gradually implemented and among other benefits, will aid physicians in prescribing more effective medications. CILPMERGE presently is being used for guidance in treating cardiovascular disease, blood clots and high cholesterol.
Information on BioMe is available here.
More for you
Loading data for hdm_tax_topic #better-outcomes...